In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Coherus BioSciences Inc.

www.coherus.com

Latest From Coherus BioSciences Inc.

Amgen's US Biosimilar Launches Are Off To A Steady Start, With A Big Coverage Decision

United HealthCare agreed to cover Mvasi and Kanjinti in a preferred position. Amgen VP-oncology sales & marketing Susan Logan talked to Scrip about the company's first US biosimilar launches.

Biosimilars Launches

Advances On the Biosimilar Litigation Battlefield

A look at the evolution of litigation, from Amgen's 'bold' at-risk launch of Herceptin and Avastin biosimilars to the jump in settlements, new battles over manufacturing information and an expected petition to the Supreme Court.

Biosimilars Intellectual Property

Coherus Set Sights On Taking Fifth Of US Pegfilgrastim Market

Having made a strong start with sales of over $120m in its first six months on the market, Coherus believes its Udenyca biosimilar could end 2019 with more than a fifth of the US pegfilgrastim market by volume.

Biosimilars Business Strategies

Amgen’s Nonconformist Position On Biosimilar Payment Policy Reflects Market Strategy

Company objects to legislative proposals that would enhance Medicare Part B reimbursement for biosimilars to boost uptake, even as it launches its first biosimilars in the US market.

Biosimilars Reimbursement
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Generic Drugs
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Dermatology
  • Gastrointestinal
  • Immune Disorders
  • Musculoskeletal & Connective Tissue Disorders
  • Ophthalmic
  • Alias(es)
  • BioGenerics Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Coherus BioSciences Inc.
  • Senior Management
  • Dennis Lanfear, Chmn., Pres. & CEO
    Jean-Frederic Viret, PhD, CFO
    Vladimir Vexler, PhD, CSO
    Darlene Horton, MD, CMO & Chief Reg. Affairs Officer
    Vince Anicetti, COO
    Erik Wiberg, VP, Corp. Dev.
  • Contact Info
  • Coherus BioSciences Inc.
    Phone: (800) 794-5434
    333 Twin Dolphin Dr., Ste. 600
    Redwood City, CA 94065
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register